Hunan Dajiaweikang Pharmaceutical Industry Stock Forum

Despite strong revenue growth, the company's P/S ratio remains lower than industry peers, indicating investor skepticism about sustained growth. The recent share price surge didn't align the P/S ratio with the industry median, hinting at potential risks pressuring the share price.

Despite industry-like revenue growth, the lower than expected P/S ratio and the falling share price suggest potential risks. Some shareholders may be more bearish than recent times would indicate, accepting lower selling prices.